Enovis Corporation (ENOV)

About Enovis Corporation

Enovis Corporation, a medical technology company, focuses on developing clinically differentiated solutions in the United States and internationally. It operates through two segments: Prevention and Recovery, and Reconstructive segments. The Prevention and Recovery segment offers rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, electrical stimulators for pain management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions. The Reconstructive segment develops, manufactures, markets, and distributes surgical solutions that restore mobility and improve patient outcomes, which includes a range of differentiated implants, instrumentation, and enabling technologies used in elective and non-elective joint replacement, limb reconstruction, and foot and ankle procedures; and products for the hip, knee, shoulder, elbow, extremity reconstruction and fixation, foot, ankle, and finger, as well as surgical productivity tools. It also manufactures and distributes a range of products which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company distributes its products through independent distributors, direct salespeople, and patients. The company was formerly known as Colfax Corporation. Enovis Corporation was founded in 1995 and is headquartered in Lewisville, Texas.

Company profile, industry and headcount are as reported by our data provider and can lag a company's own filings by a reporting period. The annual report is the authority.

Super investor ownership

10 of the funds we track reported a position in their latest SEC 13F filing. Largest first:

• Israel Englander, MILLENNIUM MANAGEMENT LLC$16.63M · 0.0% of book
• Cliff Asness, AQR CAPITAL MANAGEMENT LLC$12.23M · 0.0% of book
• Impax Asset Management, Impax Asset Management Group plc$8.78M · 0.1% of book
• Marshall Wace, MARSHALL WACE, LLP$6.10M · 0.0% of book
• Arrowstreet Capital, ARROWSTREET CAPITAL, LIMITED PARTNERSHIP$5.89M · 0.0% of book

A word of warning on reading these figures: a 13F reports the market value of a holding, so a fund that traded nothing at all still appears to have sold when the price fell. We found 102 companies where the standard reading gives the opposite answer. Only the share count is honest.

Politician trades in ENOV

Trades in ENOV disclosed by members of Congress and executive-branch officials, latest first:

• Donald J Trump · Executive branchBuy · $15,001 - $50,000 · traded 30 Apr 2026 · disclosed 1 Jul 2026
• Donald J Trump · Executive branchSell · $1,001 - $15,000 · traded 4 Jun 2024 · disclosed 22 Aug 2026

A disclosure reports a value band, not an amount, and is due up to 45 days after the trade; some arrive later. Every filer we track, each with their own page, is on the Congress trading tracker.

Common questions